Form 4 for OLMA Olema Pharmaceuticals, Inc.

Accepted 2023-11-22 00:00:00 ET · period of report 2023-11-20 · accession 0001415889-23-015457 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2023-11-22	2023-11-20	OLMA	Harmon Cyrus	Dir	A - Grant	$0.00	+15.8K	959.5K	+2%	$0
M	2023-11-22	2023-11-21+	OLMA	Harmon Cyrus	Dir	S - Sale	$14.39	-8,181	951.3K	-0.9%	-$117.7K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-11-20	A	A	15,750	$0.00	959,464	D	—	—	(F1) On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 45,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria.
2	Common	Common Stock	2023-11-21	S	D	4,192	$14.86	955,272	D	—	—	(F3) The weighted average sale price for the transaction reported was $14.86, and the range of prices was between $14.26 and $15.19. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
3	Common	Common Stock	2023-11-22	S	D	3,989	$13.90	951,283	D	—	—	(F4) The weighted average sale price for the transaction reported was $13.90, and the range of prices was between $13.62 and $14.14. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.